Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|June 1, 2005
The 2005 Buyers' Guide
S
Advertisement
This Buyers' Guide has been created as an additional service for our readers. Since technology is changing every minute, we ask that you verify details with the companies listed. The publisher does not assume responsibility or liability for errors and omissions.
Advertisement
Related to this article
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
4
Litifilimab Demonstrates Durable Skin Clearance Through 52 Weeks in Cutaneous Lupus
5